Clinical Trial Update: Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating nivolumab after induction treatment in triple-negative breast cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN